Nicox succeeds in its capital increase of 3.3 million euros

Nicox SA announced the success of its capital increase with maintenance of preferential subscription rights. This operation made it possible to raise 3.3 million euros, thanks to the issue of 13,154,900 new shares at a unit price of 0.25 euros per share, accompanied by share subscription warrants.

The company, specialized in ophthalmology and listed on Euronext Growth Paris, is thus extending its cash flow horizon until the end of February 2025. This will allow Nicox to continue the development of its main drug candidate, NCX 470, including the Phase study. 3 Denali.

Ocumension Therapeutics, a long-time partner, becomes the largest shareholder with 4.82% of the capital. Partnership discussions and evaluation of strategic options are also underway to secure the financial future.